IL6 and systemic-onset juvenile idiopathic arthritis: While the IL-6 antagonist tocilizumab has been proven to be effective in treating severe and persistent Still’s disease (5, 6), tumor necrosis factor inhibitors have been proven to have some role but seem to be replaced by anti-IL-1 and anti-IL-6 agents in terms of systemic efficacy (6).